Abbott Laboratoriesvs.Hologic
ABT vs HOLX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 11× larger than Hologic by market cap; Hologic trades at the lower P/E (31.2 vs 35.5); year to date, Hologic leads (+2.0% vs −6.9%).
Side by side
| ABT | HOLX | |
|---|---|---|
| Market cap | $193B | $17B |
| Price | $116.13 | — |
| Today | −0.5% | — |
| Return YTD | −6.9% | +2.0% |
| Return 1Y | −12.0% | −3.5% |
| P/E | 35.5 | 31.2 |
| P/S | 4.1 | 4.1 |
| P/B | 3.8 | 3.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →HologicHOLX
Women's health defines the range here, from molecular diagnostic tests to mammography systems and surgical products.
Full HOLX profile →More ABT & HOLX comparisons
Other head-to-heads in the Diagnostics segment.
See where ABT and HOLX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →